Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycidol SCHEMBL8375576 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| Glycidol SCHEMBL377563 | 0.85 | — | — | |
| Glycidol SCHEMBL2014115 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| Glycidol SCHEMBL377640 | 0.85 | — | — | |
| Glycidol SCHEMBL15684 | 0.85 | — | — | |
| SCHEMBL242398 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| SCHEMBL15579093 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TDP1TP53CYP3A4TSHR | |
| Glycidol SCHEMBL1310864 | 0.82 | — | — | |
| Glycidol SCHEMBL10872016 | 0.82 | — | — | |
| SCHEMBL942150 | 0.82 | ALDH1A1 (0.42) | ALDH1A1TDP1TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013103780-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-07-11 | — | — | WO | claimed |
| CN-112979878-A | Grease-based grafted PVC material and preparation method and application thereof | 江苏大学 | 2021-06-18 | — | — | CN | disclosed |
| US-20150071904-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | TRUSTEES OF BOSTON UNIVERSITY | 2015-03-12 | — | — | US | disclosed |
| WO-2013103780-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20060172953-A1 | Treatment of benign prostatic hyperplasia using energolytic agents | THRESHOLD PHARMACEUTICALS INC. (US) | 2006-08-03 | — | — | US | disclosed |
| EP-1592430-A4 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS | THRESHOLD PHARMACEUTICALS INC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006010073-A1 | PREVENTION OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1592430-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS | Threshold Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004064736-A2 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ENERGOLYTIC AGENTS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003027274-A2 | PURIFIED POLYPEPTIDES FROM PSEUDOMONAS AERUGINOSA | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071904-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | ROS1, NOX4, CYBB | ALDH1A1 3290/4885TDP1 2435/4885TP53 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.